Idiopathic pulmonary fibrosis (IPF) is a poorly understood disease that usually leads to death
within 5 years of diagnosis. Despite our better understanding of IPF pathogenesis, the …

Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary
fibrosis treatment by regulatory agencies and available for clinical use worldwide. These …

Idiopathic pulmonary fibrosis (IPF), the most common form of fibrosing idiopathic interstitial
pneumonia, is an inexorably progressive disease with a 5-year survival of~ 20%. In the last …

Fibrosis is the concluding pathological outcome and major cause of morbidity and mortality
in a number of common chronic inflammatory, immune-mediated and metabolic diseases …

The two novel drugs approved for IPF, pirfenidone and nintedanib, open a new scenario in
which treated patients with fibrosis will live longer, and possibly have a lower incidence of …

Idiopathic pulmonary fibrosis is a nonmalignant disease, yet it carries a prognosis akin to, or
even worse than, many cancers. Until recently, lung transplantation has been the only …

Idiopathic pulmonary fibrosis (IPF) is a devastating condition that carries a prognosis worse
than that of many cancers. A recent classification of the idiopathic interstitial pneumonias …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by
progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It …

The landscape of idiopathic pulmonary fibrosis (IPF) has changed. The significant progress
regarding our knowledge on the pathogenesis of the disease together with the experience …

Background Pirfenidone and nintedanib are the sole pharmacological therapies currently
approved for idiopathic pulmonary fibrosis (IPF). Limited comparison data is available in …